Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.

Abstract : Vascular endothelial growth factor-A, an angiogenesis stimulator expressed on both tumor endothelial and malignant T cells, is involved in tumor progression in T-leukemia/lymphoma. Here, we assessed the impact of therapeutic vascular endothelial growth factor-A blockade on tumor-endothelial cell interaction and on tumor progression. In a murine xenograft T-leukemia/lymphoma model, combined bevacizumab (monoclonal antibody against vascular endothelial growth factor-A) with doxorubicin, compared with doxorubicin alone, significantly delayed tumor growth and induced prevalence of tumor cell apoptosis over mitosis. More importantly, the combined treatment induced endothelial cell swelling, microvessel occlusions, and tumor necrosis. In vitro, co-culture of endothelial cells with T-leukemia/lymphoma cells showed that doxorubicin induced expression of intracellular cell adhesion molecule-1, provided endothelial and malignant T cells were in direct contact. This was abrogated by bevacizumab treatment with doxorubicin. Taken together, bevacizumab enhances the chemotherapeutic effect on T-leukemia/lymphoma cells. Directly targeting tumor endothelial cells might be a promising therapeutic strategy to counteract tumor progression in T-cell malignancies.
docType_s : Journal articles
Domain :


http://www.hal.inserm.fr/inserm-00741102
Contributor : Ratajczak Philippe <>
Submitted on : Thursday, October 11, 2012 - 4:00:54 PM
Last modification on : Thursday, October 11, 2012 - 4:00:54 PM

File

927.full_1_.pdf
fileSource_public_greenPublisher

Identifiers

Collections

Citation

Li Wang, Wen-Yu Shi, Fan Yang, Wei Tang, Guillaume Gapihan, et al.. Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.. Haematologica, Ferrata Storti Foundation, 2011, 96 (6), pp.927-31. <10.3324/haematol.2010.037689>. <inserm-00741102>

Export

Share

Metrics